

2007

## Structure and function studies of recombinant clusterin

Yvonne T. Gonzalez Cendales  
*University of Wollongong*

Follow this and additional works at: <https://ro.uow.edu.au/theses>

**University of Wollongong**

**Copyright Warning**

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site.

You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material.

Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily represent the views of the University of Wollongong.

---

### Recommended Citation

Gonzalez Cendales, Yvonne T, Structure and function studies of recombinant clusterin, MSc-Res thesis, Department of Biological Sciences, University of Wollongong, 2007. <http://ro.uow.edu.au/theses/68>

## **NOTE**

This online version of the thesis may have different page formatting and pagination from the paper copy held in the University of Wollongong Library.

## **UNIVERSITY OF WOLLONGONG**

### **COPYRIGHT WARNING**

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following:

Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material. Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

# **Structure and Function Studies of Recombinant Clusterin**

A thesis submitted in (partial) fulfillment of the requirements for the award of the  
degree of  
**MASTERS OF SCIENCE**  
Research

From  
**UNIVERSITY OF WOLLONGONG**

By Yvonne Teresa González Cendales  
Supervisor MARK R. WILSON

Department of Biological Sciences  
December 2007

## **DECLARATION**

This thesis is submitted in accordance with the regulations of the University of Wollongong in fulfilling the requirements for the degree Master of Biotechnology - Research. It does not incorporate any material previously published or written by any person except where due reference is made in the text. The experimental work described in this thesis is original work and has not been previously submitted for a degree or diploma at any university.

Yvonne Teresa González Cendales

December 13, 2007.

## **ACKNOWLEDGEMENTS**

I wish to acknowledge with thanks the support, guidance and patience of Professor Mark Wilson, Department of Biological Sciences, University of Wollongong, who has instructed me, given me invaluable advice and reviewed this thesis from its start to finish and without whom this project would not have been accomplished.

I also would like to thank the people in Professor Wilson's laboratory, Amy Wyatt, Elise Steward and Justin Yerbury for their advice and assistance; also to Rebecca Dabbs, who helped me to get started. And especially to Steven Poon, who has guided me through the project.

Many thanks to the people from the University of Wollongong for their continuous support and guidance, especially Mark Dowton and Ren Zhang, Department of Biological Sciences, and James Atkinson and Liz Benny from Campus East.

And finally a big thanks to the people who have helped me through these last two years, without whose support, patience and love this accomplishment would not have been possible. Thank you with all my heart, Kris Nunney, Teresa Cendales de González, Janet Thompson, Jose Francisco González, Timothy Walsh, Angela Bromley and all the Nunney family.

Yvonne Teresa González Cendales  
December, 2007.

## ABSTRACT

Clusterin is a ubiquitous secreted glycoprotein that acts as an extracellular chaperone. It effectively inhibits stress-induced protein aggregation by an ATP independent mechanism, binding to partially unfolded proteins and forming soluble high molecular weight complexes with them (Wilson and Easterbrook-Smith, 2000). A model proposed by Yerbury *et al.* (2005) suggested that if clusterin mediates the clearance and degradation of misfolded extracellular proteins *in vivo* and this action is anti-inflammatory, a recombinant form of clusterin might be therapeutically useful to clear protein debris from sites of disease and inflammation and in this way suppress pathology. The expression of recombinant mammalian proteins is often performed using mammalian or insect cells because some post-translational processes (glycosylation, phosphorylation, oligomerization, specific protein cleavage and disulfide bond formation) are not performed by bacterial cells (Sambrook *et al.*, 1989). However, since Stewart *et al.* (2007) showed that clusterin retains its chaperone function when deglycosylated and that deglycosylation did not induce major structural changes in the molecule, the possibility of producing chaperone-active human clusterin in bacteria became apparent. This thesis describes an attempt to produce a chaperone-active recombinant clusterin expressed in bacteria to provide a large scale supply of protein useful in therapeutic applications. In addition, two different commercially available recombinant clusterin proteins were compared in structure and chaperone function with human serum clusterin to provide additional insights into any functional limitations of recombinantly expressed clusterin proteins and to supply the information to the manufacturer.

Firstly, the expression of clusterin - MBP fusion protein was attempted in *E. coli* TBI but full length recombinant clusterin - MBP fusion protein was only detected as a minor species; a large part of the product was cleaved from MBP during expression and most of the MBP-clusterin fusion protein was degraded with time. Thus, because it was not possible to obtain a source of stable clusterin - MBP fusion protein, the expression of clusterin – 6xHis tag fusion protein was attempted.

Gateway® cloning technology was used for cloning and expressing clusterin – 6xHis tag fusion protein in *E. coli*. After expression, the protein was extracted and purified under denaturing conditions. The purified protein was subsequently refolded in 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, 1 mM DTT, 10% glycerol, 0.1% azide, alkylated with 50 mM IAA and dialyzed prior to developing functional and structural analyses. After expression in *E. coli* TBI, clusterin – 6xHis Tag fusion protein was detected along with disulfide-bonded high molecular weight aggregates and putative truncated products. While structural studies by CD revealed that the

predicted secondary structure content of clusterin – 6xHis tag fusion protein and plasma-derived clusterin were similar, functional analysis revealed that the former had little if any chaperone activity (its limited effects on the heat-induced precipitation of fibrinogen were not dose-dependent).

Structural (SEC, CD) and functional analyses (chaperone assays and IgG binding test) of Flag-Tagged full-length recombinant human clusterin (expressed in human embryonic kidney cells) and His-Tagged partial-length recombinant rat clusterin (expressed in *E. coli*, not post translationally processed, thus not cleaved into  $\alpha$  and  $\beta$  chains and not glycosylated) (both commercial proteins from BioVendor- Laboratory Medicine, Inc.) indicated that the recombinant proteins tested had (i) an increased proportion of high molecular weight species when compared with plasma-derived clusterin, (ii) predicted secondary structure content similar to that of plasma-derived clusterin, (iii) chaperone activity but were less effective than plasma-derived clusterin (recombinant human 28%, recombinant rat 48% less effective) and (iv) were able to bind IgG, the IgG binding activity was dose-dependent and similar to that of plasma-derived clusterin. Furthermore, the results obtained for recombinant rat clusterin suggested that the expression of chaperone active clusterin in bacteria is possible and that cleavage into  $\alpha$  and  $\beta$  chains and the C-terminus of the beta chain (residues 22-145) are not required for chaperone or IgG binding activity. Further studies will be required to optimize production of a chaperone active form of human clusterin in bacteria.

## TABLE OF CONTENTS

Title page	i
Declaration	ii
Acknowledgements	iii
Abstract	iv
Table of Contents	vi
Abbreviations	x
List of Tables	xi
List of figures	xii
 <b>1. Introduction</b>	 <b>1</b>
1.1 Clusterin Distribution	2
1.2 Clusterin structure	3
1.3 Clusterin function	4
1.3.1 Clusterin as an extracellular chaperone	5
1.3.2 Similarities between clusterin and the small heat shock proteins	6
1.3.3 Role of clusterin in extracellular quality control of protein folding	8
1.3.4 Protein folding diseases and role of clusterin	10
1.4 Aims of the project	12
 <b>2. Materials and Methods</b>	 <b>14</b>
2.1 General buffers and solutions	14
2.1.1 Buffers	14
2.1.2 Human Clusterin	14
2.2 Expression of clusterin - Maltose Binding Protein (MBP) fusion protein by induction of <i>E. coli</i> TBI pMal-c2x-clusterin clones.	14
2.2.1 Bacterial culture media	14
2.2.2 Reagents	15
2.2.3 Protein expression from pMal™ vectors	15
2.2.3.1 Analysis of plasmids for the presence of clusterin-encoding insert by restriction enzyme digestion.	16
2.2.3.2 Protein expression	16
2.2.4 Protein extraction.	16
2.2.4.1 Protocol for small scale protein extraction	17
2.2.4.2 Protocol for large scale protein extraction	17
	vi



2.3 Expression of clusterin - 6xHisTag fusion protein using an <i>E. coli</i> expression system with Gateway® cloning technology.	17
2.3.1 attB-Flanked clusterin-encoding PCR product	19
2.3.1.1 Agarose gel electrophoresis.	20
2.3.2 Creation of entry clones from attB-flanked PCR products via the BP reaction.	20
2.3.2.1 Transformation of the recombination reaction products into competent cells.	20
2.3.2.2 Analysis of plasmids for the presence of clusterin insert by restriction enzyme digestion.	21
2.3.3 Creation of expression clones by recombination of an entry clone and a destination vector via the LR reaction.	21
2.3.3.1 Transformation of expression vector into competent cells	21
2.3.3.2 Analysis of putative expression plasmids for the presence of clusterin-encoding insert by restriction enzyme digestion	21
2.3.4 Protein expression from Gateway® expression clones	21
2.3.5 Protein extraction.	22
2.3.5.1 Small scale protein extraction	22
2.3.5.2 Large scale protein extraction.	22
2.4 Purification of clusterin using Immunoaffinity chromatography	23
2.4.1 Immunoaffinity chromatography using anti-clusterin monoclonal antibody coupled immunoaffinity columns for purification of clusterin – MBP fusion protein.	23
2.4.2 Immunoaffinity chromatography using Ni-NTA immunoaffinity column for purification of clusterin - 6xHisTag fusion protein	24
2.4.3 Refolding and alkylation of clusterin - 6xHis Tag fusion protein	24
2.4.4 Concentration of protein by ultrafiltration and estimation of protein concentration by absorbance at 280 nm	25
2.5 Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE), Coomassie Blue Stain and Western Blot	25
2.5.1 Buffers and reagents	25
2.5.2 SDS-PAGE gel composition	25
2.5.3 SDS-PAGE of recombinant forms and plasma-derived clusterin	26
2.5.4 Western Blot	26
2.5.4.1 Transfer of proteins from SDS-polyacrylamide gels to nitrocellulose.	26
2.5.4.2 Immunodetection of clusterin.	26
2.5.4.3 Immunodetection of MBP fusion protein.	27
2.6 Protein precipitation assays to measure chaperone activity	27
2.7 Analyses of clusterin structure	27
2.7.1 Size exclusion chromatography (SEC)	27
2.7.1.1 SEC to evaluate the structure of clusterin-MBP fusion protein, flag-tagged recombinant human clusterin and His-tagged recombinant rat clusterin.	27
2.7.1.2 SEC to purify clusterin - 6x His Tag fusion protein.	28

2.7.2 Circular dichroism spectroscopy	28
2.7.2.1 CD to evaluate the structure of clusterin - 6x His Tag fusion protein.	28
2.7.2.2 CD to evaluate the structure of flag-tagged recombinant human clusterin and His-tagged recombinant rat clusterin (BioVendor-Laboratory Medicine, Inc).	29
2.8 IgG Binding Assays	30
2.8.1 Evaluating binding of clusterin to human IgG by ELISA.	30
<b>3. Expression, purification and characterization of clusterin - Maltose binding protein (MBP) fusion protein</b>	31
3.1 Introduction	31
3.2 Methods	31
3.2.1 Restriction digestion of purified plasmids to test for the presence of the clusterin encoding insert.	31
3.2.2 Expression and purification of clusterin - MBP fusion protein.	31
3.2.3 Analysis of recombinant clusterin structure and chaperone action.	32
3.3 Results	32
3.3.1 Restriction digestion of purified plasmids to test for the presence of the clusterin encoding insert.	32
3.3.2 Expression of recombinant clusterin protein.	33
3.3.3 Extraction and purification of clusterin – MBP fusion protein.	35
3.3.4 Large scale purification of clusterin – MBP fusion protein.	36
3.3.5 Analysis of the recombinant product structure	37
3.4 Discussion	40
<b>4. Expression, purification and characterization of clusterin - 6xHis tag fusion protein</b>	42
4.1 Introduction	42
4.2 Methods	42
4.2.1 Construction of an <i>attB</i> -flanked clusterin-encoding PCR product.	42
4.2.2 Creation of an entry clone from attB-flanked PCR products via the BP reaction.	42
4.2.3 Creation of expression clones by recombination of clusterin-pDONR™201 and the destination pET-DEST42 vector via the LR reaction.	43
4.2.4 Clusterin - 6xHis Tag fusion protein expression from Gateway® expression clones and purification by Ni-NTA affinity chromatography.	43
4.2.5 Analysis of clusterin - 6xHis tag fusion protein structure and chaperone action.	43
4.3 Results	43
4.3.1 Analysis of the <i>attB</i> -flanked clusterin-encoding PCR product	43
4.3.2 Creation of an entry clones from attB-flanked PCR products via the BP reaction.	44
4.3.3 Creation of expression clones by recombination of clusterin-pDONR™201 and pET-DEST™42 destination vector via the LR reaction.	46

4.3.4 Protein expression from Gateway® expression clones.	48
4.3.5 Analysis of the structure of the recombinant products.	49
4.3.5.1 SDS-PAGE.	49
4.3.5.2 Circular dichroism spectroscopy.	52
4.3.6 Analysis of the chaperon action of clusterin – 6xHis tag fusion product.	54
4.4 Discussion	55
 <b>5. Comparative studies of human plasma-derived clusterin and recombinant human and rat clusterin</b>	 57
5.1 Introduction	57
5.2 Methods	58
5.3 Results	58
5.3.1 Analysis of the structure of the recombinant products	58
5.3.1.1 SDS-PAGE	58
5.3.1.2 Size exclusion chromatography.	59
5.3.1.3 Circular dichroism spectroscopy.	61
5.3.2 Analysis of the function of the recombinant products.	62
5.3.2.1 Protein precipitation assays	62
5.3.2.2 IgG binding ELISA assay.	63
5.4 Discussion	64
 <b>6. Conclusions</b>	 66
 <b>References</b>	 70

## ABBREVIATIONS

Bovine serum albumin	BSA
Citrate synthase	CS
Dithiothreitol	DTT
Iodoacetamide	IAA
Heat-denatured casein	HDC
Immunoglobulin G	IgG
Phosphate buffered saline	PBS
Tris EDTA	TE
Maltose Binding Protein	MBP
Lauria Bertani	LB
Isopropylthio- $\beta$ -galactoside	IPTG
Tris Acetate EDTA	TAE
PBS/0.1% sodium azide	PBS/Az
Sodium dodecylsulphate polyacrylamide gel electrophoresis	SDS-PAGE
Size Exclusion Chromatography	SEC
Circular dichroism spectroscopy	CD
Millidegrees	mdeg
mean residue ellipticity	$\theta_{MRE}$

## LIST OF TABLES

Table 1	Band patterns expected and detected in the agarose gel showed in Figure 9 of <i>pMal-c2x-clusterin</i> plasmid pMal-c2x-clusterin after digestion after digestion with <i>Bgl</i> I, <i>Sma</i> I and <i>Xba</i> I	33
Table 2	Band patterns expected and detected in the agarose gel shown in Figure 19 resulting from restriction digestion of entry clone clusterin-pDONR™201 plasmid with <i>Eco</i> RI and <i>Bgl</i> II.	45
Table 3	Band patterns expected and detected in the agarose gel showed in Figure 20 of expression clone clusterin-pET-DEST™42 after digestion with <i>Sfi</i> I.	47
Table 4	Predicted percentages of secondary structural features for clusterin – 6xHis Tag fusion protein and plasma-derived clusterin based on Far-UV CD data and predicted by computational analyses using the prediction program ContinLL	53
Table 5	Predicted percentages of secondary structural features for plasma-derived clusterin, recombinant human clusterin and recombinant rat clusterin based on Far-UV CD data and predicted by computational analyses using the prediction program ContinLL.	61
Table 6	Comparison of characteristics of recombinant human and rat clusterin expressed in <i>E. coli</i> .	68

## LIST OF FIGURES

Figure 1	Predicted structure of human clusterin	3
Figure 2	Theoretical model for extracellular quality control of non-native extracellular proteins by chaperones	8
Figure 3	pMal™ vector series c2x	15
Figure 4	Integration-excision reaction between <i>E. coli</i> and $\lambda$ bacteriophage in the switch between the lytic and lysogenic pathway	17
Figure 5	Outline of the BP and LR reactions in the Gateway® cloning technology	18
Figure 6	Antibody affinity chromatography	23
Figure 7	CD spectra shown by three common motifs of secondary structure	29
Figure 8	Diagram illustrating clusterin-encoding sequence inserted downstream from the malE gene of <i>E. coli</i> TB1 in the pMal-c2x vector.	32
Figure 9	Image of an ethidium bromide stained 1% agarose gel showing the results of restriction digestion of pMal-c2x-clusterin plasmids.	33
Figure 10	Image of anti-clusterin Western blot probing for expressed clusterin - MBP fusion protein in non-reduced whole cell lysates of <i>E. coli</i> TBI pMal-c2x-clusterin clones.	34
Figure 11	Image of anti-MBP Western Blot probing for clusterin - MBP fusion protein in non-reduced whole cell lysates of <i>E. coli</i> TBI pMal-c2x-clusterin clones.	35
Figure 12	Image of anti-clusterin Western blot analysis of non-reduced soluble and insoluble fractions prepared from induced <i>E. coli</i> TBI pMal-c2x-clusterin.	36
Figure 13	Image of anti-clusterin Western Blot analysis of non-reduced soluble extract from large scale culture of induced <i>E. coli</i> TBI pMal-c2x-clusterin	37
Figure 14	Absorbance (280 nm) traces for size exclusion chromatographic analysis of plasma-derived clusterin and recombinant human clusterin	38
Figure 15	Line of best fit for protein mass versus the elution volume for protein standards after SEC	39
Figure 16	Images of SDS-PAGE (a) and Immunoblot (b) of recombinant and plasma-derived clusterin	39

Figure17	Image of an ethidium bromide stained 1% agarose gel showing attB-clusterin PCR product.	44
Figure 18	Diagram illustrating the entry clone (clusterin-pDONR™201).	44
Figure19	Image of an ethidium bromide stained 1% agarose gels showing Entry clone (pDONR™201+ attB Clusterin) before and after restriction digestion with <i>EcoRI</i> (a) and with <i>HindIII</i> (b)	45
Figure 20a	Figure 20a. Diagram illustrating the resulting expression clone (clusterin - pET-DEST™42).	47
Figure 20b	Image of an ethidium bromide stained 0.8% agarose gel showing putative clusterin - pET-Dest™42 expression plasmids before and after restriction digestion with <i>SfiI</i> .	48
Figure 21	Image of Western Blot analysis using anti-clusterin antibodies of samples of the extracted protein fractions (soluble protein fraction and the inclusion bodies) to corroborate the presence of clusterin – 6xHis Tag fusion protein.	49
Figure 22	Image of a reducing SDS-PAGE gel stained with Coomassie Blue showing analysis of clusterin - 6xHis Tag fusion protein after Ni-NTA affinity chromatography.	49
Figure 23	Diagram illustrating the elution fractions obtained by SEC (a) and image of SDS-PAGE gel stained with Coomassie Blue showing analysis of the eluted fractions (b).	50
Figure 24	Image of reducing SDS-PAGE gel stained with Coomassie Blue showing analysis of clusterin - 6xHis Tag fusion protein purified by Ni-NTA chromatography.	51
Figure 25	Image of Western Blot analysis of preparations of clusterin - 6xHis tag fusion protein using anti-clusterin antibodies.	52
Figure 26	CD spectra of clusterin - 6xHis tag fusion protein and plasma-derived clusterin	53
Figure 27	Influence of clusterin proteins on the heat-induced aggregation of fibrinogen	54
Figure 28	Image of SDS-PAGE gel stained with Coomassie Blue showing analysis of recombinant human clusterin, recombinant rat clusterin and plasma-derived human clusterin	58
Figure 29	Absorbance (280 nm) traces for size exclusion chromatographic analyses of plasma-derived clusterin, recombinant human clusterin and recombinant rat clusterin.	59
Figure 30	Line of best fit for protein mass versus the elution volume for protein standards after SEC.	60

Figure 31	CD spectra of recombinant proteins and plasma-derived clusterin. The relation between $\theta_{MRE}$ and wavelength were plotted for plasma-derived clusterin, recombinant human and rat clusterin proteins.	61
Figure 32	Influence of clusterin proteins on heat-stressed fibrinogen aggregation.	63
Figure 33	Binding of plasma-derived clusterin, recombinant rat and recombinant human clusterin to human IgG	64